Breakthrough in Lung Cancer Treatment: Predicting Immunotherapy Response

Researchers at the University of Queensland, led by Associate Professor Arutha Kulasinghe, have made significant strides in predicting patient responses to immunotherapy for lung cancer, specifically targeting the drug Keytruda. This study analyzed lung biopsies from nearly 250 patients with non-small cell lung cancer, the most prevalent form of lung cancer, which affects approximately 90% of lung cancer patients globally. The research utilized advanced microscopy and artificial intelligence to examine millions of cells within each biopsy, aiming to identify cellular patterns that could indicate a patient's likelihood of responding to immunotherapy.

ABC News AustraliaScientists create nanoparticle vaccine that prevents cancerNature

The study, published in *Nature Genetics*, introduced a "Google Maps approach" to cancer analysis, where the spatial arrangement and communication between immune cells and tumor cells were found to be predictive of treatment outcomes. Kulasinghe noted that certain immune cells must not only be in proximity to tumor cells but also in an optimal state to effectively target and destroy them. The research identified a "molecular fingerprint" within the tumor samples that could help screen lung cancer patients for potential immunotherapy effectiveness.

ABC News AustraliaScientists create nanoparticle vaccine that prevents cancerNature

The findings suggest that oncologists could potentially assess lung cancer patients before administering immunotherapy, thereby personalizing treatment plans. Kulasinghe expressed hope that further studies would validate these findings, leading to new treatment combinations that could enhance patient responses to immunotherapy. Lung cancer advocate Michel Itel, who has lived with advanced lung cancer since 2017, praised the research as revolutionary, emphasizing its potential to change how lung cancer is studied and treated.

ABC News AustraliaScientists create nanoparticle vaccine that prevents cancerNature

Mark Brooke, CEO of Lung Foundation Australia, described the research as an incredible breakthrough, highlighting the importance of targeting the right treatment to the right patient at the right time. He noted that lung cancer is often stigmatized as a smoker's disease, but the study included both smokers and non-smokers, challenging this misconception. The five-year survival rate for lung cancer patients has improved from 16% to 26% over the past decade, attributed to advancements in precision medicine and targeted therapies.

ABC News AustraliaScientists create nanoparticle vaccine that prevents cancerNature

While the study has garnered excitement within the cancer research community, it also raises questions about the accessibility of immunotherapy, which can be prohibitively expensive, costing between $400,000 and $500,000 annually per patient. Critics may argue that without addressing cost barriers, the benefits of such predictive methodologies may not reach all patients.

Scientists create nanoparticle vaccine that prevents cancer

• “We wanted to find out if there were patterns in the tissues that were predictive of response or resistance to immunotherapies,” — Arutha Kulasinghe, Associate Professor, University of Queensland

ABC News Australia

• “Increasingly lung cancer is treated by targeting the right treatment to the right patient at the right time, so this new way of looking at lung cancers is quite exciting for the patient community.” — Mark Brooke, CEO, Lung Foundation Australia

ABC News Australia

• “I think it's definitely going to be a game changer in how we do disease analysis,” — Michel Itel, Lung Cancer Advocate

ABC News Australia

The ongoing research at the University of Queensland represents a pivotal moment in lung cancer treatment, with the potential to significantly improve patient outcomes through personalized medicine.

ABC News Australia